Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lixte Biotechnology Holdings Inc.

1.33
-0.0502-3.64%
Post-market: 1.340.0101+0.76%19:15 EDT
Volume:3.28K
Turnover:4.37K
Market Cap:3.57M
PE:-0.92
High:1.37
Open:1.34
Low:1.32
Close:1.38
Loading ...

Lixte Biotechnology Converts Preferred Stock to Common

TIPRANKS
·
21 May

Lixte Biotechnology Holdings Inc. Announces Conversion of Series A Preferred Shares into Common Stock

Reuters
·
21 May

Lixte Biotech Hldgs Q1 EPS $(0.29) Up From $(0.43) YoY

Benzinga
·
12 May

Lixte Biotechnology Provides Update on Progress With Proprietary Compound, Lb-100, to Treat Ovarian and Colorectal Cancer

THOMSON REUTERS
·
27 Mar

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

GlobeNewswire
·
27 Mar

BRIEF-Lixte Biotechnology terminates sales agreement with Wallachbeth Capital

Reuters
·
11 Mar

Lixte Adds NorthWestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

THOMSON REUTERS
·
25 Feb

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

GlobeNewswire
·
25 Feb

Lixte Biotechnology Closes $1.1 Million Direct Offering

MT Newswires Live
·
14 Feb

Lixte Biotechnology announces closing of $1.05M registered direct offering

TIPRANKS
·
13 Feb

Lixte Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
13 Feb

Lixte Biotechnology Announces $1.05 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
11 Feb

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
11 Feb

Lixte Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

THOMSON REUTERS
·
11 Feb

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

GlobeNewswire
·
11 Feb

BRIEF-Lixte Biotechnology Holdings' Eric Forman Resigns As VP And COO Of Lixte Biotech Effective As Of Dec 31

Reuters
·
28 Dec 2024

Lixte Biotechnology Holdings - on Dec 23, Eric Forman Resigns as Vp and COO of Lixte Biotech Effective as of Dec 31

THOMSON REUTERS
·
28 Dec 2024